Glomerulonephritis Global Market Report 2025

The glomerulonephritis market size has grown strongly in recent years. It will grow from $11.06 billion in 2024 to $11.64 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth during the historic period was driven by the rising prevalence of kidney disorders, the occurrence of infections such as post-streptococcal glomerulonephritis, increased research and development efforts, a higher incidence of kidney failure, and greater awareness of kidney diseases.

The glomerulonephritis market size is expected to see strong growth in the next few years. It will grow to $14.14 billion in 2029 at a compound annual growth rate (CAGR) of 5%. The projected growth in the forecast period can be attributed to the increasing incidence of diabetes, an aging population, rising healthcare expenditures, a growing number of dialysis patients, and a surge in autoimmune disease cases. Key trends expected during this period include the introduction of new treatments and therapies, advancements in diagnostic technologies, the development of novel therapeutics, increased collaboration between companies, and the growing use of intravenous immunoglobulin therapy.

The increasing prevalence of kidney disorders is expected to drive the growth of the glomerulonephritis market. Kidney disorders encompass a range of conditions that impair the kidneys' ability to filter waste, maintain fluid balance, and regulate essential bodily functions. The rising incidence of these disorders is linked to factors such as aging populations, increasing rates of chronic diseases such as diabetes and hypertension, and lifestyle habits. Kidney disorders contribute to glomerulonephritis by triggering immune system dysfunction, chronic inflammation, or structural damage, ultimately leading to impaired kidney function. For example, in December 2024, the Australian Institute of Health and Welfare reported that chronic kidney disease (CKD) mortality rates increased by 4.2% in 2021 and 6.2% in 2022. Additionally, CKD was recorded in approximately 2 million hospitalizations in 2021-22, accounting for 18% of all hospitalizations in Australia. As kidney disorders become more prevalent, the demand for glomerulonephritis treatments is expected to rise.

Leading companies in the glomerulonephritis market are focusing on developing innovative non-immunosuppressive treatments to meet unmet medical needs and improve patient outcomes. Non-immunosuppressive treatments are designed to treat conditions without compromising immune function. In September 2024, Travere Therapeutics Inc., a US-based biopharmaceutical company, launched FILSPARI (sparsentan), which received FDA approval for treating IgA nephropathy, a common kidney disease. FILSPARI is the only non-immunosuppressive treatment proven to significantly slow the decline of kidney function in affected patients. This approval marks a significant advancement in the treatment of IgA nephropathy, providing a new option for patients who previously had limited choices. Travere's success reflects a growing commitment to developing innovative therapies for kidney disease.

In May 2023, Rona Therapeutics Inc., a China-based biopharmaceutical company, entered into a partnership with Keymed Biosciences Inc. to develop novel treatments for glomerulonephritis. This collaboration focuses on creating first-in-class siRNA therapeutics to address the urgent need for new medicines in this field. Keymed Biosciences Inc., also based in China, specializes in biotechnology and is dedicated to advancing treatments for glomerulonephritis.

Major players in the glomerulonephritis market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Asahi Kasei Medical Co. Ltd., Boehringer Ingelheim International GmbH, DaVita Inc., Biogen Inc., Merit Medical Systems Inc., Apellis Pharmaceuticals Inc., MorphoSys AG, Travere Therapeutics Inc., Vera Therapeutics Inc., Calliditas Therapeutics AB, Omeros Corporation, Otsuka Pharmaceutical Co. Ltd., Aurinia Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., and NovelMed Therapeutics Inc.

North America was the largest region in the glomerulonephritis market in 2024. The regions covered in glomerulonephritis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Glomerulonephritis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Glomerulonephritis is a kidney disorder characterized by inflammation of the glomeruli, the tiny filters in the kidneys responsible for removing waste and excess fluids from the blood. It can be caused by infections, autoimmune diseases, or other underlying conditions, leading to symptoms such as blood in the urine, proteinuria, and swelling. If left untreated, it can progress to chronic kidney disease or kidney failure.

The primary types of glomerulonephritis include acute and chronic glomerulonephritis. Acute glomerulonephritis is a sudden inflammation of the kidneys, often triggered by infections, and requires prompt treatment to prevent long-term complications. Diagnosis is conducted through various methods, including urine and blood tests, imaging tests, and kidney biopsy. Treatment options include medication, surgery, dialysis, and other interventions. The condition is managed through multiple distribution channels, including hospital pharmacies and retail pharmacies, and is utilized by various end-users such as hospitals and specialty clinics.

The glomerulonephritis market research report is one of a series of new reports that provides glomerulonephritis market statistics, including the glomerulonephritis industry global market size, regional shares, competitors with the glomerulonephritis market share, detailed glomerulonephritis market segments, market trends, and opportunities, and any further data you may need to thrive in the glomerulonephritis industry. This glomerulonephritis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The glomerulonephritis market consists of revenues earned by entities by providing services such as immunosuppressive therapy, blood pressure control, and kidney transplants. The market value includes the value of related goods sold by the service provider or included within the service offering. The glomerulonephritis market also includes sales of complement-level test kits, urine protein test kits, and medication. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.